`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`COALITION FOR AFFORDABLE DRUGS VIII, LLC
`Petitioner,
`
`v.
`
`THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
`Patent Owner
`
`
`
`Case: IPR2015-01836
`Patent No. 7,932,268
`
`
`
`UPDATED LIST OF PATENT OWNER’S EXHIBITS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER’S LIST OF EXHIBITS
`
`University of Pennsylvania Patent License Agreement (May 19,
`2006)
`NDA #203858, Sponsor’s Background Package For the
`Endocrinologic and Metabolic Drugs Advisory Committee
`Meeting, Advisory Committee Briefing Materials (Oct. 17, 2012)
`ClinicalTrials.gov: Safety, Tolerability, and Efficacy of
`Microsomal Triglyceride Protein (MTP) Inhibitor, available at
`https://clinicaltrials.gov/ct2/show/NCT01556906?term=NCT0155
`6906&rank=1
`Marina Cuchel et al., Inhibition of Microsomal Triglyceride
`Transfer Protein in Familial Hypercholesterolemia, 356 (2) N.
`ENG. J. MED. 148-56 (Jan. 11, 2007).
`U.S. Appl. No. 14/075,483, Amendment and Response to Final
`Office Action (Nov. 30, 2015)
`FDA News Release, FDA approves new orphan drug for rare
`cholesterol disorder, available at
`http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncement
`s/ucm333285.htm (Dec. 26, 2012)
`Marina Cuchel et al., Efficacy and safety of a microsomal
`triglyceride transfer protein inhibitor in patients with homozygous
`familial hypercholesterolemia: a single-arm, open-label, phase 3
`study, 381 THE LANCET 40-46 (Jan. 5, 2013)
`Joseph Walker et al., New Hedge Fund Strategy: Dispute the
`Patent, Short the Stock, THE WALL STREET JOURNAL (Apr. 7,
`2015), available at
`http://www.wsj.com/articles/hedgefundmanagerkylebasschallenge
`sjazzpharmaceuticalspatent1428417408
`Intentionally Left Blank
`Patentee’s Observations in reply to the Notice of Opposition by
`Dr. Evan Stein, European Patent No. 1 725 234
`
`Ex. 2001
`
`Ex. 2002
`
`Ex. 2003
`
`Ex. 2004
`
`Ex. 2005
`
`Ex. 2006
`
`Ex. 2007
`
`Ex. 2008
`
`Ex. 2009
`
`Ex. 2010
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Ex. 2011
`
`Ex. 2012
`
`Ex. 2013
`
`Ex. 2014
`
`Ex. 2015
`
`Ex. 2016
`
`Ex. 2017
`
`The Pink Sheet, MTP inhibitor research discontinued (July 31,
`2000)
`Aegerion Pharmaceuticals, Inc., U.S. Securities and Exchange
`Commission, Form 10-K (March 2, 2015)
`Aegerion Pharmaceuticals, Inc., U.S. Securities and Exchange
`Commission, Form 10-K (March 18, 2013)
`Aegerion Pharmaceuticals, Inc., Third Quarter 2015 Earnings
`Conference Call, available at
`http://files.shareholder.com/downloads/AEGR/0x0x860375/8F9C
`1576-D084-454D-BBCF-
`C656C341E238/AEGR_Q3_15_Slides_Final.pdf (Nov. 9, 2015)
`JUXTAPID label (2012)
`Center For Drug Evaluation And Research, Application Number
`203858Orig1s00, Summary Basis for Regulatory Action (Dec. 21,
`2012)
`Declaration of Nicholas K. Mitrokostas in support of Patent
`Owner’s Motion for Pro Hac Vice Admission of Nicholas K.
`Mitrokostas Under 37 C.F.R. § 42.10(c)
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that the foregoing “UPDATED LIST OF
`
`PATENT OWNER’S EXHIBITS” was served electronically via e-mail on May 5,
`
`2016 on the following:
`
`
`Dr. Gregory Gonsalves
`2216 Beacon Lane
`Falls Church, Virginia 22043
`(571) 419-7252
`gonsalves@gonsalveslawfirm.com
`
`Christopher Casieri
`McNeely, Hare & War LLP
`12 Roszel Road, Suite C104
`Princeton, NJ 08540
`(609) 731-3668
`chris@miplaw.com
`
`Counsel for Petitioner Coalition
`for Affordable Drugs VIII, LLC
`
`
`
`
`
`
`
`
`
`
`
`
`
`/April E. Weisbruch/
`April E. Weisbruch
`
`
`
`Dated: May 5, 2016